Global Information
회사소개 | 문의 | 위시리스트

Alnylam Pharmaceuticals, Inc. : 제품 파이프라인 리뷰

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 07월 상품 코드 224581
페이지 정보 영문 88 Pages
가격
US $ 1,500 ₩ 1,776,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,552,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,329,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Alnylam Pharmaceuticals, Inc. : 제품 파이프라인 리뷰 Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016
발행일 : 2016년 07월 페이지 정보 : 영문 88 Pages

앨나일람(Alnylam Pharmaceuticals, Inc.)은 RNA 간섭(RNAi)에 근거한 신규 치료제 발견·개발·판매에 특화한 바이오 의약품 기업입니다. 앨나일람에서는 현재 'Alnylam 5x15' 계획을 추진하여 유전자 요인에 의한 질환용 RNAi 기반 치료제 개발에 임하고 있습니다.

미국 바이오 의약품 기업인 앨나일람(Alnylam Pharmaceuticals, Inc.)의 의약품 연구개발 진척 상황에 대해 분석하고, 제품 파이프라인 구조, 전체적인 임상시험 진척 상황, 주요 파이프라인 제품 프로파일과 개발 상황, 기업 개요와 최신 동향 등의 정보를 전해드립니다.

목차

1. Alnylam Pharmaceuticals, Inc. : 현황

  • 기업 개요
  • 주요 정보
  • 주요 데이터

2. 연구개발(R&D) 상황 개요

  • 주요 치료 영역

3. 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 파이프라인 제품 : 단일요법(Monotherapy)
  • 파이프라인 제품 : 라이선싱 아웃 제품(Out-Licensed Products)
    • 라이선싱 아웃 제품/병용요법(Combination Treatment) 모달리티

4. 파이프라인 제품 개요

  • 후기 단계 파이프라인 제품
    • 3상 제품/병용요법 모달리티
  • 임상시험 단계 파이프라인 제품
    • 2상 제품/병용요법 모달리티
    • 1상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 제품/병용요법 모달리티
    • 신규 치료제 발견 단계 제품/병용요법 모달리티

5. 치료제 개요

  • patisiran
    • 제품 개요
    • 작용기전
    • 연구개발(R&D) 진전
  • ALN-TTRSC
  • asvasiran sodium
  • ALN-AT3
  • ALN-PCS02
  • ALN-PCSsc
  • ALN-TTR-01
  • ALN-VSP
  • ALN-AAT
  • ALN-ANG
  • ALN-APC
  • ALN-AS1
  • ALN-CC5
  • ALN-HPN
  • ALN-HTT
  • ALN-TMP
  • 암 및 바이러스 감염을 위한 수지상 세포 백신
  • LNP-dsP21-322-2'F
  • 파킨슨병을 위한 RNAi 치료제
  • SIRNA-034
  • 희귀질환을 위한 마이크로RNA

6. 파이프라인 분석

  • 표적별
  • 투여 방법별
  • 분자 종류별
  • 작용기전별

7. 파이프라인 제품의 최신 동향

8. 개발 휴지 상태인 제품

9. 기업 성명

10. 사업소 및 자회사

  • 본사
  • 기타 사업소 및 자회사

부록

도표

LSH 14.06.09

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
  • The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alnylam Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alnylam Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alnylam Pharmaceuticals, Inc. Snapshot
    • Alnylam Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Alnylam Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alnylam Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance
    • Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Drug Profiles
    • patisiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PCSsc
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fitusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AAT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-CC5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-GO1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HBV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AS1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TTRsc02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-VSP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AC3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AGT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-ANG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PDL
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TMP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology and Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HDV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Genetic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Hepatic Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alnylam Pharmaceuticals, Inc. - Pipeline Analysis
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Alnylam Pharmaceuticals, Inc. - Dormant Projects
  • Alnylam Pharmaceuticals, Inc. - Company Statement
  • Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alnylam Pharmaceuticals, Inc., Key Information
  • Alnylam Pharmaceuticals, Inc., Key Facts
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase III, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase II, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase I, 2016
  • Alnylam Pharmaceuticals, Inc. - Preclinical, 2016
  • Alnylam Pharmaceuticals, Inc. - Discovery, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Alnylam Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top
전화 문의
F A Q